Brian Orelli, PhD

It's a biotech thing.

Pricing pressure has investors worried about the pharma's future drug sales.

Delays rock the biotech.

The cancer-test company continues to increase revenue, resulting in a smaller loss for the second quarter.

Up by double digits after its earnings release, Exelixis is pleasing investors with the early launch of Cabometyx.

It was a solid second quarter from the spine-care company.

The lab test maker's QIAsymphony platform is driving sales of disposables that run on the machine.

After announcing a manufacturing issue for Auryxia yesterday, the biotech's stock fell further on Tuesday.

Sales of the biotech's newest cystic fibrosis drug are off to a good start, but further growth will need to come from expanding the number of patients it's approved to treat.

It was a strong second quarter for the maker of veterinary tests.

The biotech is scheduled to report its first sales of Cabometyx this week.

Investors pile in as the biotech awaits a decision from the FDA.

The cancer genetics test maker reports on Tuesday.

Investors are excited about positive clinical trial results for nusinersen in infants with spinal muscular atrophy.

Sales of the biotech's only drug continue to climb.

A strong second quarter for the healthcare and lab supply company boosted share prices.

After a strong start to the year, the biotech increased its full-year earnings guidance.

Investors are excited about the healthcare company selling off its unprofitable segments.

No direct news for the biotech, but these seem to have added up to a big one-day gain.

A solid quarter from the healthcare company.